17 completed, 4 active not recruiting, 1 recruiting, 1 terminated. 24 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 17, Active not recruiting 4, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Urethral Neoplasms: new trials by email Literature Review of Urethral Neoplasms trials Research Report on Urethral Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64Cu-GRIP B in Patients With Advanced Malignancies Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET) - Prostate Cancer, Renal Cancer | Phase 1 / Phase 2 | Recruiting | Rahul Aggarwal | 91 | 2023-05-25 | 2026-03-17 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma Avelumab, AVB-S6-500 - Urothelial Carcinoma | Phase 1 | Active not recruiting | University of Oklahoma | 19 | 2020-02-17 | 2026-03-13 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour MRx0518 Capsules, MRx0518/placebo Capsules - Melanoma, Breast Cancer | Phase 1 | Unknown | Imperial College London | 120 | 2019-04-10 | 2022-08-11 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Carboplatin, Cisplatin, Docetaxel - Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 15 | 2019-01-11 | 2025-11-12 |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer enfortumab vedotin (EV), pembrolizumab, cisplatin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Terminated | Astellas Pharma Global Development, Inc. | 348 | 2017-10-11 | 2026-03-24 |
| Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride - Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma | Phase 1 | Completed | University of California, Davis | 32 | 2015-09-01 | 2022-10-18 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Ramucirumab, Pembrolizumab - Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Completed | Eli Lilly and Company | 175 | 2015-07-29 | 2024-07-31 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Enzalutamide, Cisplatin, Gemcitabine - Bladder Cancer, Carcinoma, Transitional Cell | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 10 | 2015-02-11 | 2019-08-01 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Vinflunine, Sorafenib - Urothelial Carcinoma, Bladder Cancer | Phase 1 | Completed | Dr Anders Ullén | 22 | 2012-05-01 | 2019-04-26 |
| Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors Gemcitabine, Carboplatin, Lenalidomide - Urethral Neoplasms, Neoplasms, Urethral | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2011-09-26 | 2026-10-16 |
| A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Cisplatin, Gemcitabine, ALT-801 - Transitional Cell Carcinoma of Bladder, Urethra Cancer | Phase 1 / Phase 2 | Completed | Altor BioScience | 68 | 2011-09-06 | 2024-06-25 |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium cisplatin, gemcitabine hydrochloride, temsirolimus - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 1 / Phase 2 | Completed | Cardiff University | 15 | 2008-02-01 | 2018-02-06 |
| Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Bortezomib, Gemcitabine, Doxorubicin - Solid Tumor, Urethral Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 80 | 2006-09-28 | 2026-10-09 |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma ziv-aflibercept - Cancer | Phase 1 | Completed | Regeneron Pharmaceuticals | 25 | 2004-01-01 | 2016-06-03 |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma ziv-aflibercept - Cancer | Phase 1 | Completed | Regeneron Pharmaceuticals | 25 | 2004-01-01 | 2016-06-03 |
| Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium Recombinant Interferon Alfa - Bladder Cancer, Urethral Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2003-12-01 | 2015-05-14 |
| Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions recombinant adenovirus-hIFN-beta - Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 2003-04-01 | 2020-05-13 | |
| Thalidomide and Docetaxel in Treating Patients With Advanced Cancer docetaxel, thalidomide - Cancer | Phase 1 | Completed | Case Comprehensive Cancer Center | 26 | 2002-07-01 | 2010-06-11 |
Showing 20 of 24. Sign in to see all of them.
Urinary Bladder Neoplasms (23) · Prostatic Neoplasms (10) · Ureteral Neoplasms (10) · Neoplasms (9) · Carcinoma, Hepatocellular (7) · Carcinoma, Non-Small-Cell Lung (7) · Carcinoma, Transitional Cell (7) · Endometrial Neoplasms (7) · Testicular Neoplasms (7) · Uterine Cervical Neoplasms (7) · Vaginal Neoplasms (7) · Vulvar Neoplasms (7) · Anus Neoplasms (6) · Breast Neoplasms (6)
Female Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (24) · Male Urogenital Diseases (24) · Neoplasms by Site (24) · Urethral Diseases (24) · Urogenital Diseases (24) · Urologic Diseases (24) · Urogenital Neoplasms (23) · Urologic Neoplasms (23) · Urinary Bladder Diseases (22) · Neoplasms by Histologic Type (17) · Neoplasms, Glandular and Epithelial (16) · Carcinoma (15) · Neoplasms (15) · Genital Diseases (12)
Gemcitabine (7) · Cisplatin (5) · pembrolizumab (4) · Carboplatin (3) · Docetaxel (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Trastuzumab (2) · aflibercept (2) · enfortumab vedotin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · ALT-801 (1) · Biopsy (1) · Bortezomib (1) · CTLA-4 Antigen (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (2) · Regeneron Pharmaceuticals (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Altor BioScience (1) · Astellas Pharma Global Development, Inc. (1) · Cardiff University (1) · Case Comprehensive Cancer Center (1) · Dr Anders Ullén (1) · Eli Lilly and Company (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Imperial College London (1) · Jonsson Comprehensive Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1)
United States (21) · Canada (3) · United Kingdom (3) · France (2) · Spain (2) · Denmark (1) · Germany (1) · Italy (1) · Japan (1) · Puerto Rico (1) · Sweden (1)
William P. Tew, MD (2) · Abhishek Tripathi, MD (1) · Andrea B Apolo (1) · Andrea B Apolo, M.D. (1) · Anthony W. Tolcher, MD (1) · Arlene Siefker-Radtke, MD (1) · Arnold Chin (1) · Ashish M. Kamat, MD (1) · Changting Meng, MD (1) · Charles Erlichman, MD (1) · Daniel H. Sterman, MD (1) · Dr Jonathan Krell (1) · Jason Lukas, MD, PhD (1)
PMID 19949018, PMID 22002018, PMID 18470481, PMID 20068553, PMID 29853658, PMID 30552156, PMID 31301962, PMID 32915679, PMID 33068794, PMID 35031545, PMID 36041086, PMID 37369081, PMID 38215355, PMID 38954785, PMID 39536751
2015 (1), P30CA016672 (1), P30CA043703 (1), P50CA091846 (1), R01CA229354 (1), R01CA258297 (1), U01CA076576 (1), UM1CA186644 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)